The Dermatology Digest

NOVEMBER 20, 2024

Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx, UCB) for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). Today’s approval of bimekizumab-bkzx is an exciting time for the hidradenitis suppurativa community, offering a new possibility for the treatment of people in the U.S.

Safety 78

Safety Sustainability Clinic Medical 78

Southeastern Esthetics Institute

AUGUST 23, 2016

Estheticians must obtain written permission and treatment plans through the physician overseeing the practice, with monitoring by the physician of all notations within patient charts, products and modalities used, and any other thought process made throughout the duration of treatment.

Esthetician 195

Esthetician Esthetics Document Office 195

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 66

Dermatitis Safety Eczema Dermatology 66

The Dermatology Digest

MARCH 18, 2024

Food and Drug Administration (FDA) has accepted Journey Medical’s New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024. “We

Rosacea 74

Rosacea Medical Office Clinic 74

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

The Dermatology Digest

JUNE 5, 2024

Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks.

Safety 73

Safety Office Facials Therapy 73

Dermatology Times

OCTOBER 3, 2024

Brad Glick, DO, MPH, discusses how to effectively introduce photodynamic therapy (PDT) into a dermatology clinic by outlining necessary equipment and setup, providing guidance on essential patient discussions for treatment introduction, and sharing strategies to ensure treatment efficacy while prioritizing patient safety and satisfaction.

Clinic 36

Clinic Therapy Safety Dermatology 36

The Dermatology Digest

DECEMBER 18, 2024

The clinical results demonstrated that STEQEYMA and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of safety and efficacy. “STEQEYMA is now the latest biologic in our immunology portfolio, joining ZYMFENTRA (infliximab-dyyb). .”

Portfolios 68

Portfolios Injections Office Safety 68

The Dermatology Digest

JANUARY 18, 2024

The new data is part of the READY phase III clinical trial program. Patient satisfaction was also high, with up to 91% reporting satisfaction with simultaneous treatment at one month. At the conference, Galderma will also present from the phase IV STAR study on Alluzience (abobotulinumtoxinA solution) for the treatment of frown lines.

Safety 74

Safety Clinic Treatments Dermatology 74

The Dermatology Digest

APRIL 16, 2024

Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use as a biosimilar to Stelara for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. says Thomas Rainey, Senior Vice President, U.S.

Partnerships 74

Partnerships Injections Safety Marketing 74

Dermatology Times

OCTOBER 14, 2024

Panelists discuss how research in pediatric psoriasis management needs more attention on long-term safety, treatment efficacy, and the psychosocial impact of the disease on young patients.

Clinic 36

Clinic Treatments Safety Management 36

The Dermatology Digest

MAY 16, 2024

trial site in MoonLake Immunotherapeutics’ global Phase 3 clinical program, VELA, evaluating sonelokimab in hidradenitis suppurativa (HS). We are making significant progress in establishing clinical trial sites to enroll 800 patients, and we eagerly anticipate reporting the week 16 primary endpoint readout around mid-2025.”

Safety 68

Safety Clinic Dermatology Office 68

The Dermatology Digest

MAY 17, 2024

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed durable response rates and consistent safety in patients with moderate-to-severe plaque psoriasis after four years of continuous treatment, according to results from the POETYK PSO long-term extension (LTE) trial. patient-years (PYs) for the safety analyses. Year 4, 0.1)

Safety 36

Safety Sustainability Clinic Innovations 36

The Dermatology Digest

JANUARY 20, 2024

By blocking MRGPRX2 activation and degranulation of mast cells, EVO756 has the potential to be a first-in-class oral treatment for a variety of mast cell-mediated diseases, including chronic spontaneous urticaria and inflammatory itch. Evommune, Inc.

Safety 74

Safety Office Dermatitis Clinic 74

The Dermatology Digest

JULY 24, 2024

This BLA/MAA for BAT2206 is based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. A Biologics License Application seeking approval for BAT2206 is also currently under review by the China National Medicinal Product Administration (NMPA).

Dermatology 78

Dermatology Sales Marketing Safety 78

Dermatology Times

JUNE 19, 2024

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Treatments 36

Treatments Dermatitis Safety Clinic 36

The Dermatology Digest

JULY 18, 2024

Fully 50% of patients are now enrolled in Dermata’s pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) study of DMT310, the Company reports. The primary endpoints are the mean change from baseline in inflammatory and noninflammatory lesion counts and the Investigator Global Assessment (IGA) treatment response.

Clinic 36

Clinic Dermatology Collagen Exfoliation 36

Aesthetics Advisor

OCTOBER 7, 2023

Based on rapidly emerging clinical trials evidence, the FLCCC team has developed the I-MASK+ protocol for prophylaxis and at home treatment of early stage COVID-19 and has now divided the I-MASK protocol into I-CARE and I-PREVENT protocols. Treatment is therefore highly stage-specific. Treatment of BA.4/BA.5/BQ.1.1

Treatments 69

Treatments Therapy Medical Vitamin C 69

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). Zoryve foam was approved by the U.S.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

The Dermatology Digest

MARCH 5, 2024

FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment. ” In a study, more than 80% of subjects had at least a one-point improvement in moderate to severe temple hollowing three months after treatment, and the improvement lasted for more than one year (73%).

Portfolios 74

Portfolios Injections Training Facials 74

The Dermatology Digest

JANUARY 15, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE) with limited systemic exposure, according to two studies presented at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii. This trial included samples from 313 people on active treatment.

Safety 36

Safety Eczema Dermatology Treatments 36

The Dermatology Digest

DECEMBER 4, 2024

Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Restem’s umbilical cord outer lining stem cells (ULSCs) program for the treatment of dermatomyositis (DM) and polymyositis (PM). The estimated incidence of PM/DM is approximately 5 to 22 cases per 100,000 individuals. PHOTO CREDIT: DermNet The post U.S.

Treatments 36

Treatments Office Therapy Clinic 36

Eminence Organics

FEBRUARY 27, 2024

Salt Saunas: Benefits Of Salt In Spa Treatments Think your spa has experienced every trend? Along with these newer therapies, we'll also discuss scientifically proven salt treatments, like salt scrubs, to give you a comprehensive view. Benefits | Scrubs & Other Salt Treatments | Can Everyone Enjoy Salt Treatments?

Treatments 59

Treatments Therapy Training Exfoliation 59

The Dermatology Digest

SEPTEMBER 20, 2024

s Investigational Device Exemption (IDE) application to initiate a multi-center study for the treatment of recurrent cutaneous Squamous Cell Carcinoma (cSCC) in immunocompromised patients using Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT). Food and Drug Administration (FDA) has approved Alpha Tau Medical Ltd.’s Dr. Robert B.

Office 74

Office Safety Clinic Medical 74

The Dermatology Digest

JULY 29, 2024

is initiating the Onward Phase 3 Clinical Program evaluating ESK-001, an oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe plaque psoriasis. Key secondary endpoints will include PASI 90, PASI 100 and sPGA 0 measured at Weeks 16 and 24, and safety and tolerability. Alumis Inc.

Clinic 36

Clinic Safety Office Treatments 36

The Dermatology Digest

APRIL 4, 2024

Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for bimekizumab-bkzx (Bimzelx, UCB), an interleukin(IL)-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). at UCB in a news release. Bimzelx was approved in the U.S. In the U.S.,

Safety 57

Safety Injections Clinic Therapy 57

The Dermatology Digest

FEBRUARY 8, 2024

Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Taking Seb Derm Seriously The U.S.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

MARCH 5, 2024

Food and Drug Administration (FDA) has given its nod to Letybo (foletibotulinumtoxinA) for the treatment of moderate-to-severe glabellar lines in adults. Now, there are six neuromodulators approved for cosmetic use in the U.S.: and Europe.

Branding 74

Branding Injections Safety Facials 74

The Dermatology Digest

MAY 16, 2024

million, five-year National Institutes of Health (NIH) U01 grant to investigate dupilumab (Dupixent, Sanofi & Regeneron) as a treatment for children with alopecia areata. Current treatment options for alopecia areata harbor negative side effects for long-term use. Dr. Guttman. “If

Eczema 69

Eczema Dermatitis Safety Innovations 69

Dermatology Times

SEPTEMBER 25, 2023

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Safety 36

Safety Clinic Treatments 36

The Dermatology Digest

SEPTEMBER 23, 2024

Delgocitinib, a topical pan-Janus kinase (JAK) inhibitor, is the first topical treatment to be specifically indicated for adult patients living with moderate to severe CHE across the European Union (EU) for whom topical corticosteroids are inadequate or inappropriate. Both trials met their primary and all secondary endpoints. In the U.S.,

Eczema 66

Eczema Safety Dermatology Clinic 66

AAAMS

APRIL 17, 2024

Introduction to Aesthetic Treatments and Botox Aesthetic treatments have gained significant popularity in the realm of beauty and self-care. The growing demand for Botox treatments has increased the need for skilled professionals. It’s not just about looking younger but also feeling confident. What is Botox Certification?

Treatments 52

Treatments Injections Wrinkles Safety 52

The Dermatology Digest

JANUARY 14, 2024

The research was presented at the 2024 Winter Clinical Dermatology Conference – Hawaii in Honolulu. The PDE4 inhibitor is the first topical treatment for seborrheic dermatitis with a new mechanism of action in more than 20 years. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. Zoryve foam; 48.3%

Dermatitis 72

Dermatitis Dermatology Office Safety 72

The Dermatology Digest

FEBRUARY 26, 2024

Sonelokimab is a novel investigational nanobody for the treatment of inflammatory disease. The number of patients, the straightforward trial design, the similarity of protocol to the Phase 2 trial, and the identification of the HS dose, collectively, enhance the clarity of SLK’s clinical development and displays promise for the HS franchise.

Office 74

Office Clinic Safety Innovations 74

The Dermatology Digest

MAY 22, 2024

The first patient has been dosed in Zai Lab’s global Phase 2 clinical trial of ZL-1102, a topical anti-IL-17 investigational therapy for the treatment of mild to moderate chronic plaque psoriasis. ZL-1102 is the first IL-17 targeted topical treatment in development for patients with less severe forms of CPP.

Clinic 36

Clinic Therapy Safety Treatments 36